JC-171

Research use only, not for human use.

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM.

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM; interferes with NLRP3/ASC interaction induced by LPS/ATP stimulation both in vtiro and in vivo; delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE).

JC-171 (0-100 μM) blocks NLRP3 inflammasome activation and IL-1β production in primary macrophages dose dependently.Cell Viability AssayCell Line:J774A.1 murine macrophage cells Concentration:0-100 μM.Incubation Time:0.5 h (before LPS (1 μg/mL) treatment for 4.5 h).Result:Inhibited the release of IL-1β in J774A.1 cells upon stimulation with LPS/ATP.

JC-171 treatment delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mouse. Animal Model:Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide emulsified in Complete Freund’s Adjuvant (CFA) on day 0 followed by injection of 200 ng of pertussis toxin.Dosage:100 mg/kg, 10 mg/kg.Administration:IP days 0, 1 and 2; and every other days thereafter (100 mg/kg). Initiated when the clinical scores of individual mice have reached 1 (flaccid tail), and given every other day (10 mg/kg). Result:Efficiently suppressed EAE progression compared with vehicle treatment.Resulted in a substantial decrease in the frequency of MOG35–55-specific Th17 cells in the spleens and spinal cords of EAE mice.

JC171

NF-κB

NOD

NOD

——

——

2112809-98-8

384.831

C16H17ClN2O5S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (649.64 mM)

O=C(NCCC1=CC=C(S(=O)(NO)=O)C=C1)C2=CC(Cl)=CC=C2OC

5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide

(-20℃)

With Ice Pack

≥ 2 years